Evan David Seigerman
Stock Analyst at BMO Capital
(3.58)
# 856
Out of 5,238 analysts
55
Total ratings
47.92%
Success rate
8.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $68.26 | +46.50% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $111.38 | +16.72% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $714.89 | +18.90% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $331.70 | +12.15% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $46.07 | -0.15% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $4.07 | +170.27% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $201.55 | +19.08% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $30.78 | -15.53% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.40 | +25.00% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $10.11 | -1.09% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $39.10 | +155.75% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.68 | +40.19% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $8.35 | -64.07% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $948.45 | -58.25% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $68.26
Upside: +46.50%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $111.38
Upside: +16.72%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $714.89
Upside: +18.90%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $331.70
Upside: +12.15%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $46.07
Upside: -0.15%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $4.07
Upside: +170.27%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $201.55
Upside: +19.08%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $30.78
Upside: -15.53%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.40
Upside: +25.00%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $10.11
Upside: -1.09%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $39.10
Upside: +155.75%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.68
Upside: +40.19%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $8.35
Upside: -64.07%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $948.45
Upside: -58.25%